Calidi Biotherapeutics Statistics
Share Statistics
Calidi Biotherapeutics has 33.59M
shares outstanding. The number of shares has increased by -59.37%
in one year.
| Shares Outstanding | 33.59M |
| Shares Change (YoY) | -59.37% |
| Shares Change (QoQ) | 38.38% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 6,146 |
| FTD / Avg. Volume | 1.08% |
Short Selling Information
The latest short interest is 171.13K, so 0.54% of the outstanding
shares have been sold short.
| Short Interest | 171.13K |
| Short % of Shares Out | 0.54% |
| Short % of Float | 0.57% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -0.42 and the forward
PE ratio is -0.83.
Calidi Biotherapeutics's PEG ratio is
-0.01.
| PE Ratio | -0.42 |
| Forward PE | -0.83 |
| PS Ratio | 0 |
| Forward PS | 1.9 |
| PB Ratio | 6 |
| P/FCF Ratio | -0.47 |
| PEG Ratio | -0.01 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Calidi Biotherapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.08,
with a Debt / Equity ratio of 4.59.
| Current Ratio | 1.08 |
| Quick Ratio | 1.08 |
| Debt / Equity | 4.59 |
| Debt / EBITDA | -0.32 |
| Debt / FCF | -0.36 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-790,821.43 |
| Employee Count | 28 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 14K |
| Effective Tax Rate | -0.06% |
Stock Price Statistics
The stock price has increased by -82.33% in the
last 52 weeks. The beta is 1.2, so Calidi Biotherapeutics's
price volatility has been higher than the market average.
| Beta | 1.2 |
| 52-Week Price Change | -82.33% |
| 50-Day Moving Average | 0.61 |
| 200-Day Moving Average | 1.18 |
| Relative Strength Index (RSI) | 32.83 |
| Average Volume (20 Days) | 567,495 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -21.78M |
| Net Income | -22.14M |
| EBITDA | -21.78M |
| EBIT | -22.57M |
| Earnings Per Share (EPS) | -2.97 |
Full Income StatementBalance Sheet
The company has 9.59M in cash and 7.04M in
debt, giving a net cash position of 2.56M.
| Cash & Cash Equivalents | 9.59M |
| Total Debt | 7.04M |
| Net Cash | 2.56M |
| Retained Earnings | -121.72M |
| Total Assets | 14.18M |
| Working Capital | 731K |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -19.69M
and capital expenditures 0, giving a free cash flow of -19.71M.
| Operating Cash Flow | -19.69M |
| Capital Expenditures | n/a |
| Free Cash Flow | -19.71M |
| FCF Per Share | -2.46 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
